Simplify Health Care ETF

UnitedHealth Group stock plummets over 40% amid regulatory concerns and audit results

Sanofi and Regeneron Obtain Approval for Dupixent for Severe Asthma in Children Aged 6 to 11 from Japan's Ministry of Health

Jim Cramer says Eli Lilly's GLP-1 pill is 'going to revolutionize everything'.

Gilead's Seladelpar Approved in Bo'ao, Hainan

UnitedHealth Group options were active on December 22, with balanced bull and bear sentiment

Bernstein Analyst Maintains Buy Rating on Amgen

FlyteHealth and Eli Lilly Collaborate to Launch New Obesity Management Medication Access Program

Gilead's HIV Preventive Drug Yeytuo Approved in the UK

Gilead Sciences Exercised Option on Assembly Biosciences' Project and Paid $35 Million

UnitedHealth expands coverage to include Deep TMS therapy for adolescents with major depressive disorder

Yahoo Finance publishes analysis indicating UnitedHealth Group has a high debt burden

Eli Lilly initiates a Phase I clinical trial in China for its pan-KRAS inhibitor, LY4066434.

KMG Fiduciary Partners LLC Increases Holdings in Eli Lilly

Abivax Soars on Reports of Potential Eli Lilly Acquisition

Congress Asset Management Reduced Holdings in Eli Lilly in Q3

Bank of America Maintains 'Buy' Rating on Eli Lilly, Expects Full Value to be Realized by 2027

Beech Hill Advisors Inc. Increased Holdings in UnitedHealth Group in Q3

JPMorgan Names Eli Lilly a Top Large-Cap Pharma Stock for 2026

Analysis suggests UnitedHealth Group's stock appears cheap but may not be attractive enough

Eli Lilly Achieves Breakthrough with Oral Weight-Loss Drug in Maintaining Weight Reduction

Starfighters Space

Haoxin

Sidus Space

Mega Fortune

Jyong Biotech

Hycroft Mining

Velo3D

Tradr 2X Long QBTS Daily ETF

Creative Media & Community Trust

Tradr 2X Long FLY Daily ETF

AMGN

TECH

Bio-Techne Corp.'s stock rose 1.18% to $58.96 on Monday, marking its third consecutive day of gains. Despite this, it underperformed compared to competitors like Amgen Inc. and Charles River Laboratories, which saw higher gains. Bio-Techne remains 25.63% below its 52-week high of $79.28. The S&P 500 and Dow Jones also saw gains on the same day.

Dow Jones

Charles River Laboratorie

Amgen

Bio-Techne

Bio-Techne Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

SNYNF

REGN

Regeneron Pharmaceuticals and Sanofi announced that Japan's Ministry of Health, Labour and Welfare approved Dupixent® (dupilumab) for children aged 6 to 11 with severe asthma. This approval is based on a Phase 3 trial showing significant reduction in exacerbations and improved lung function. Dupixent is the first biologic to show such benefits in this age group. It is already approved for various conditions in over 60 countries.

StockTitan

Sanofi

Regeneron Pharma

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma | REGN Stock News

Regeneron Pharmaceuticals Inc. (REGN) stock rose 1.48% to $779.36 on Monday, outperforming some competitors. The S&P 500 Index increased by 0.64% and the Dow Jones Industrial Average by 0.47%. This marks the stock's second consecutive day of gains, closing 1.47% below its 52-week high. Trading volume was below the 50-day average.

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

GILD

Gilead Sciences Inc. will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 11:15 a.m. PT. The live webcast will be available at investors.gilead.com, with a replay accessible for 30 days. Disclaimer: This AI-generated content is for informational purposes only and not financial, investment, or legal advice.

Reuters

Gilead Sciences

Gilead Sciences Executives to Present at J.P. Morgan Healthcare Conference

Regeneron Pharmaceuticals Inc. will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via the "Investors & Media" page on Regeneron's website, with a replay and transcript available for 30 days. This announcement was originally published by Regeneron via GlobeNewswire on December 22, 2025.

Regeneron to Present at J.P. Morgan Healthcare Conference

MarketBeat's stock screener tool highlights seven pharmaceutical stocks to watch: Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Gemini Therapeutics, Novo Nordisk, and Cytokinetics. These stocks are driven by clinical-trial results, regulatory approvals, and healthcare policy, offering growth potential but also high volatility. Eli Lilly, Pfizer, and Bristol Myers Squibb have recently raised dividends, signaling strength. Investors should consider these stocks for their potential upside.

Market Beat

Bristol Myers Squibb

Eli Lilly

Top Pharmaceutical Stocks To Follow Now - December 22nd

ABVX

Health care stocks rose, with the NYSE Health Care Index up 0.5% and the XLV ETF up 0.6%. Abivax shares surged over 16% amid acquisition talks with Eli Lilly, whose shares fell 0.3%. Johnson & Johnson shares increased 0.6% after EU approval for Tremfya. Zenas BioPharma shares rose nearly 16% ahead of phase 3 results for obexelimab, as noted by Wedbush.

fidelity

Abivax SA

Johnson & Johnson

Health Care Select Sector SPDR

Sector Update: Health Care Stocks Higher in Afternoon Trading

Gilead Sciences has licensed Assembly Bio's long-acting HSV drugs, ABI-1179 and ABI-5366, following promising Phase 1b data. This marks Gilead's first advancement under their collaboration with Assembly Bio. The agreement includes a $35 million payment to Assembly Bio, with potential for $330 million in milestones and royalties. Gilead will handle further development and commercialization. Additionally, Gilead's lenacapavir was approved in the UK for HIV-1 prevention. Gilead shares were slightly down at $124.02.

benzinga_article

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes

The North American Income Trust plc reported a NAV total return of 2.5% for November 2025 and 7.9% over the past year, with a share price total return of 12.2%. The trust invests mainly in US equities, with significant exposure to financials and health care sectors. Top holdings include Chevron, CVS Health, and Philip Morris International. The reference index is the Russell 1000 Value Index.

Phillip Morris

Chevron

CVS Health

The North American Income Trust plc publishes update on portfolio strategy and performance

UnitedHealth Group has unveiled a 23-point action plan following an independent audit, aiming for transparency and operational improvement. The audit, initiated amid federal probes into Medicare practices, revealed areas for improvement in authorization timelines and documentation. UnitedHealth expects 65% of actions to be completed by 2025. The audit is part of CEO Steve Hemsley's efforts to set a new transparency standard. UnitedHealth's stock has dropped 35% year-to-date. Additional findings will be released next year.

Unitedhealth

UnitedHealth Unveils 23-Point Action Plan Following Independent Business Audit

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen with a price target of $335. Piper Sandler's David Amsellem also issued a Buy rating, while Truist Financial maintained a Hold rating. Breen, focusing on healthcare stocks, has a 20.1% average return and an 89.19% success rate. The news highlights analyst opinions and ratings on Amgen's stock.

Tip Ranks

Amgen (AMGN) Receives a Buy from Bernstein

CRSP

William Blair analyst Sami Corwin maintains a Buy rating on CRISPR Therapeutics, citing promising autoimmune and oncology data, and a strategic partnership with Eli Lilly. The zugo-cel results show potential in autoimmune cases and best-in-class response rates in lymphoma. The Eli Lilly collaboration could enhance strategic opportunities. H.C. Wainwright also reiterates a Buy rating with an $80 target.

CRISPR Therap

CRISPR Therapeutics: Early Autoimmune Promise, Best-in-Class Oncology Data, and Eli Lilly Partnership Support Buy Rating

FlyteHealth announced a new access pathway for obesity management medication for self-insured organizations, in collaboration with Eli Lilly. This initiative aims to address challenges in obesity management by offering a comprehensive care model that integrates cardio-kidney-metabolic treatment. The program includes AI-driven care plans and coordination through EMR integration, aiming to improve health outcomes and cost efficiency for employers. FlyteHealth's CEO emphasized the goal of reducing fragmentation and improving care access, while Eli Lilly's VP highlighted the importance of flexible solutions for employers.

prnewswire

11:00 ET
			
			
				FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

Gilead Sciences' HIV PrEP drug, lenacapavir, has been approved in the UK for twice-yearly injections to prevent HIV-1. This follows approvals in the US and Europe. The drug, branded as Yeytuo, offers a long-acting preventative option, reducing the risk of HIV-1 transmission. The UK aims to end new HIV transmissions by 2030. The drug's cost and NHS availability remain concerns. Gilead has allowed generics in 120 countries to improve accessibility. WHO endorses the drug for its efficacy and convenience.

Pharmaceutical Technology

UK approves Gilead’s twice-yearly HIV PrEP drug

Eli Lilly (NYSE: LLY) is trading near its 52-week high, driven by strong momentum and positive news. The stock has risen from $778 to $1,071 this year. Short-term momentum is strong, but long-term fundamentals are mixed. The Trade Engine Score is 61.23, indicating moderate strength. The next earnings date is 2026-02-04, with revenue estimates at $17.96 billion. Analyst sentiment is positive, with limited upside from current levels. Technical indicators show strong momentum but potential for short-term pullbacks.

Talkmarkets

Eli Lilly - Momentum Near 52‑Week High As Trade Engine Flags Moderate Strength